In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Astrana Health's current price sits 10.5% below a high-confidence fair value of $42.64, with DCF suggesting substantial upside but P/E and EV/EBITDA valuations notably lower, signaling conflicting signals. Financial health scores reflect poor profitability and efficiency, increasing risk despite moderate liquidity. Monte Carlo analysis shows high volatility and downside risk (16.7%), indicating potential for both significant gains and losses.